(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Computerized Moderation: Tracking down Equilibrium in the Advanced Age - 2Authentic Urban areas: Rich Legacy and Lively Societies
- 3Putin says Russian forces will seize capital of Zaporizhzhya
- 4Figuring out the Justification for Separation: To blame and No-Shortcoming
- 5How did I get my own unique set of fingerprints?
- A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
- 6 Tire Brands Reasonable for Seniors
- The most effective method to Involve Handshakes for Compromise and Compromise
- Vote In favor of Your Favored Comupter Game
- 2024's Savvy Home Gadgets for an Associated Way of life
- 6 Agreeable Earphones To Wear
- Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- Sports Shoes of 2024: Upgrade Execution and Solace
- Unusual 'ingredients' helped stars form in a galaxy near the Milky Way
